News

Under the terms of the agreement, Animas will contribute up to $750,000 to DexCom to offset certain development, clinical and regulatory expenses. The agreement is non-exclusive and does

These contracts, which are with an international biotechnology company, cover regulatory submission services, support of new clinical trials, and changes-of-scope for existing studies. The therapeutic areas covered in

CellzDirect provides hepatocyte-based cell products and related services used in the testing of new drugs. The transaction is subject to customary closing conditions and is expected to close

Lindsay Donald, vice president of Ashuren Pharmaceutical & Healthcare, said: “The decision to rename the Pharmaceutical & Healthcare Division as ‘Ashuren Health Sciences’ was taken in order to

As part of the collaboration, Celltrion will provide process development expertise and supply clinical and commercial material to support the clinical development program for CSL 360 and commercialization

New study results show that Menveo was well-tolerated and generated high levels of immunogenicity in infants against meningococcal serogroups A, C, W-135 and Y with a standard infant

In the studies reported, SF1126 showed favorable pharmacokinetics and pharmacodynamic effects as indicated by inhibition of downstream signaling elements both in vitro and in vivo. In addition, SF1126

The Safety Monitoring Committee (SMC) reviewed the safety data from the first group of patients that have completed 70 days in the study. On the basis of the

The OB-202 study is a 28 week, randomized, double blind, placebo controlled, efficacy and safety study of Qnexa in the glycemic management of obese type 2 diabetics. The